In pharmacoeconomic evaluation, ‘technology’ is used to mean a drug or other treatment that is being assessed.
T
Tezepelumab (Tezspire®). HTA ID: 23025
| Assessment Status | Awaiting full HTA submission from Applicant |
| HTA ID | 23025 |
| Drug | Tezepelumab |
| Brand | Tezspire® |
| Indication | Tezepelumab (Tezspire®) is indicated as add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma, who are inadequately controlled despite high-dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment. |
| Assessment Process | |
| Rapid review commissioned | 10/05/2023 |
| Rapid review completed | 15/06/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that tezepelumab not be considered for reimbursement at the submitted price*. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/02/2024 |
| Pre-submission consultation with Applicant | 05/03/2024 |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Time Horizon
Period of time over which costs and outcomes are measured in economic evaluation.
Transition Probability
The probability that the health of a patient changes from one health state to another health state within a given period
